Prostanoids for the management of glaucoma.

Article Details

Citation

Copy to clipboard

Arranz-Marquez E, Teus MA

Prostanoids for the management of glaucoma.

Expert Opin Drug Saf. 2008 Nov;7(6):801-8. doi: 10.1517/14740330802465474 .

PubMed ID

18983226 [ View in PubMed

]

Abstract

BACKGROUND: Prostanoids are the newest pharmacologic group of ocular hypotensive drugs for clinical management of glaucoma. The group includes four chemical compounds structurally derived from naturally-occurring prostaglandin (PG) F(2). Prostanoids have been divided into PG analogues (unoprostone, latanoprost and travoprost) and prostamides (bimatoprost) because of differences in molecular structures. The drugs share a novel mechanism of action that produces a potent ocular hypotensive effect and a novel local adverse effect of increased iridial pigmentation. OBJECTIVE: To summarise the pharmacologic and clinical data regarding the effectiveness and safety of prostanoids in clinical glaucoma management. METHODS: The review was supported by a literature search of peer-reviewed publications, based on medical information available in databases such as PubMed. RESULTS/CONCLUSION: The prostanoids began a treatment revolution not only because of their novel mechanism of action but also as a result of a new local side effect.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Travoprost	Prostaglandin F2-alpha receptor	Protein	Humans	Yes	Agonist	Details